XNAS · Healthcare · Biotechnology
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | Q1 2026 | -0.70 | -0.73 | -4.29% | $0 | ❌ Miss | +0.00% | -4.31% | — |
| 2026-03-31 | Q4 2025 | -0.56 | -0.78 | -39.29% | $0 | ❌ Miss | -4.40% | -10.38% | -0.94% |
| 2025-11-13 |
| Q3 2025 |
| -0.91 |
| -0.59 |
| +35.16% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
Showing last 3 quarters.